drug · small molecule
somatriptan albumin bound LA
Marketedupdated 3mo agoby Novo Nordisk AS🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for growth and 2 investigational indications.
targets
Growth hormone receptor
all catalysts(9)
approval · 9
Aug 28, 2020
approval
$NVO45.89-1.78%
SOGROYA (SOMAPACITAN-BECO) — FDA approval
somatriptan albumin bound LA
→
Oct 1, 2021
approval
$NVO45.89-1.78%
SOGROYA (SOMAPACITAN-BECO) — FDA approval
somatriptan albumin bound LA
→
Oct 1, 2021
approval
$NVO45.89-1.78%
SOGROYA (SOMAPACITAN-BECO) — FDA approval
somatriptan albumin bound LA
→
Apr 28, 2023
approval
$NVO45.89-1.78%
SOGROYA (SOMAPACITAN-BECO) — FDA approval
somatriptan albumin bound LA
→
Jan 31, 2025
approval
$NVO45.89-1.78%
SOGROYA (SOMAPACITAN-BECO) — FDA approval
somatriptan albumin bound LA
→
Jul 9, 2025
approval
$NVO45.89-1.78%
SOGROYA (SOMAPACITAN-BECO) — FDA approval
somatriptan albumin bound LA
→
Feb 27, 2026
approval
$NVO45.89-1.78%
SOGROYA (SOMAPACITAN-BECO) — FDA approval
somatriptan albumin bound LA
→
Feb 27, 2026
approval
$NVO45.89-1.78%
SOGROYA (SOMAPACITAN-BECO) — FDA approval
somatriptan albumin bound LA
→
Feb 27, 2026
approval
$NVO45.89-1.78%
SOGROYA (SOMAPACITAN-BECO) — FDA approval
somatriptan albumin bound LA
→
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that